Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 3/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | NPY1R | P25929 | 1/20 | 0.62 |
| ▸ | NPY2R | P49146 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18613405 | 0.92 | ADRB1 (0.55) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| SCHEMBL30515407 | 0.91 | NPY1R (0.58) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| SCHEMBL8892157 | 0.89 | ADRB1 (0.66) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| SCHEMBL13077582 | 0.89 | ADRB1 (0.54) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| SCHEMBL18613406 | 0.88 | NPY1R (0.53) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| SCHEMBL11320142 | 0.87 | ADRB1 (0.63) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| SCHEMBL4456681 | 0.87 | NPY1R (0.67) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| SCHEMBL13040110 | 0.87 | ADRB1 (0.53) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| SCHEMBL26265017 | 0.87 | ADRB2 (0.50) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| SCHEMBL29627098 | 0.86 | ADRB2 (0.52) | ADRB1ADRB2CYP2D6NR3C1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047608-A1 | Method of Treatment and Pharmaceutical Composition for Morning Hypertension | Dharma Laboratories LLC (US) | 2022-02-17 | — | — | US | disclosed |
| CN-113143877-A | Preparation method of metoprolol succinate pellet sustained-release tablet | 苏州康恒研新药物技术有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-111517967-A | Method for synthesizing metoprolol succinate isomer impurity | 山东齐都药业有限公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-110790672-A | Method for synthesizing metoprolol succinate ortho-isomer impurity | 山东齐都药业有限公司 | 2020-02-14 | — | — | CN | disclosed |
| US-20190000802-A1 | DRUG COMBINATION PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USING THEM | VICUS THERAPEUTICS LLC (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180169069-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS LLC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20170333396-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS LLC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20160158198-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS LLC (US) | 2016-06-09 | — | — | US | disclosed |
| EP-2374508-A1 | Combination of angiotension receptor blockers (ARB) and NSAIDs for use in ameliorating cachexia | Vicus Therapeutics SPE 1, LLC (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2374458-A1 | Combination of an ACE inhibitor and an NSAID for use in ameliorating cachexia/SIRS | Vicus Therapeutics SPE 1, LLC (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20080033027-A1 | Drug combination pharmaceutical compositions and methods for using them | VICUS THERAPEUTICS SPE 1, LLC (US) | 2008-02-07 | — | — | US | disclosed |
| WO-2008012346-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION OF METOPROLOL AND PROCESS FOR ITS PREPARATION | FARMAPROJECTS, S. A. (ES) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007141593-A2 | PROCESS FOR THE PREPARATION OF METOPROLOL AND ITS SALTS | MEDICHEM, S.A. (US) | 2007-12-13 | — | — | WO | disclosed |
| EP-1842534-A1 | Metoprolol succinate extended release tablets and methods for their preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-10-10 | — | — | EP | disclosed |
| US-20070202172-A1 | Metoprolol succinate E.R. tablets and methods for their preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-30 | — | — | US | disclosed |
| US-20070202162-A1 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS | DR. REDDY'S LABORATORIES, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070053983-A1 | Extended release compositions of metoprolol succinate | JAIN GIRISH | 2007-03-08 | — | — | US | disclosed |
| US-20070009589-A1 | EXTENDED RELEASE COMPOSITIONS | DR. REDDY'S LABORATORIES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20040156903-A1 | Metering and packaging of controlled release medication | MICRODOSE THERAPEUTX, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070053983-A1 | Extended release compositions of metoprolol succinate | SUCLG2, SUCLA2, BPHL | ADRB1 24/4885ADRB2 31/4885CYP2D6 339/4885 |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | APOB, MMAB, CBS | ADRB1 874/4885ADRB2 803/4885CYP2D6 1097/4885 |
| US-20070202162-A1 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS | ADRB3, ADRB2, ADRB1 | ADRB1 3/4885ADRB2 2/4885CYP2D6 140/4885 |
| US-20070202172-A1 | Metoprolol succinate E.R. tablets and methods for their preparation | SUCLG2, SUCLA2, SUCNR1 | ADRB1 4/4885ADRB2 7/4885CYP2D6 160/4885 |
| US-20070009589-A1 | EXTENDED RELEASE COMPOSITIONS | MYL6, THEM6, ATP2A3 | ADRB1 18/4885ADRB2 10/4885CYP2D6 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.